Clinical Trial: Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer

U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07817082) titled 'Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer' on Sept. 08.

Brief Summary: This is a single-center, single-arm, open-label phase II exploratory study. A total of 30 patients aged 18-75 years with ECOG PS 0-1, pathologically confirmed advanced breast cancer with ultra-low HER2 expression will be enrolled. Eligible patients must have at least one measurable lesion and have received 1-2 lines of prior systemic therapy for advanced disease. All participants receive intravenous SHR-A1811 at 4.8 mg/kg every 3 weeks, until disease progression, intolerable adverse events or other discontinuation criteria. The primar...